$16.48
$-0.94 (-5.40%)
End-of-day quote: 05/17/2024
NasdaqCM:TGTX
TG Therapeutics Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$233.66M | $2.79M | $6.69M | $0.15M | $0.15M | $0.15M | $0.15M | $0.15M | $0.15M | $0.15M | $0.15M | $0.02M | |
| GM % | Gross Margin % |
|
93.95% | 90.48% | 88.19% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | |
| OM | Operating Margin |
|
8.83% | -69.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| EPS | Earnings Per Share |
|
$0.00 | $0.09 | $-1.46 | $-2.63 | $-2.42 | $-1.96 | $-2.30 | $-1.91 | $-1.60 | $-1.38 | $-1.64 | $-0.70 | $-1.17 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| PR % | Payout Ratio % |
|
0.00% | -0.00% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Sha. | Shares |
|
141.79m | 137.65m | 131.22m | 129.79m | 102.29m | 77.77m | 66.82m | 48.14m | 46.69m | 38.53m | 27.26m | 19.19m | |
| OCF | Operating Cash Flow |
|
$-31.41M | $-176.17M | $-295.63M | $-214.51M | $-132.81M | $-128.93M | $-93.76M | $-61.59M | $-44.69M | $-35.06M | $-10.74M | $-5.19M | |
| FCF | Free Cash Flow |
|
$40.03M | $-176.18M | $-296.04M | $-214.86M | $-133.91M | $-129.02M | $-93.77M | $-61.94M | $-44.73M | $-35.08M | $-10.83M | $0.00M | |
| FCFS | Free Cash Flow Per Share |
|
$-0.22 | $-1.30 | $-2.24 | $-1.86 | $-1.50 | $-1.71 | $-1.51 | $-1.26 | $-0.98 | $-1.03 | $-0.42 | $-0.40 |
